These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 38284983)

  • 21. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S; Shih JY; Jang TW; Liam CK; Yu Y
    Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
    Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
    Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M; Singhal MK; Kamle MS
    Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
    van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM
    PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib.
    Kuo CS; Huang CH; Liu CY; Pavlidis S; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Target Oncol; 2019 Aug; 14(4):433-440. PubMed ID: 31346928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
    Huang CT; Lin CA; Su TJ; Yang CY; Tsai TH; Hsu CL; Liao WY; Chen KY; Ho CC; Yu CJ
    BMC Cancer; 2023 Mar; 23(1):234. PubMed ID: 36915101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
    Wagener-Ryczek S; Heydt C; Süptitz J; Michels S; Falk M; Alidousty C; Fassunke J; Ihle MA; Tiemann M; Heukamp L; Wolf J; Büttner R; Merkelbach-Bruse S
    BMC Cancer; 2020 May; 20(1):408. PubMed ID: 32397977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
    BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
    Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
    Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
    Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of rebiopsy methods and clinical features on T790M mutation after first-line EGFR-TKI treatment failure.
    Zhou J; Li Y; Zhang Y; Dai H; Guo S
    Future Oncol; 2021 Jul; 17(19):2475-2488. PubMed ID: 33769072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation Analysis between T790M Status and Clinical Characteristics of Patients with EGFR-sensitive Mutation Advanced NSCLC who Progressed after the First Generation and First-line EGFR-TKIs Administration: A Real-world Exploratory Study.
    Zhen Y; Xu YB; Deng RY; Li M; Ma MT; Zhou ZG; Meng QJ; Gong YN; Zhao LY; Liu YB
    Comb Chem High Throughput Screen; 2024; 27(6):845-853. PubMed ID: 37282652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
    Yoshimura A; Yamada T; Okura N; Takeda T; Furutani W; Kubota Y; Shiotsu S; Hiranuma O; Nishioka N; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
    BMC Cancer; 2018 Dec; 18(1):1241. PubMed ID: 30537950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.